Protein detail
UPAR
Urokinase plasminogen activator surface receptor (U-PAR) (uPAR) (Monocyte activation antigen Mo3) (CD antigen CD87)
Protein symbol UPAR | UniProt ID | EVMP score 0.50 |
Frequency 2 | Transmembrane count | Protein classification Cancer-related genesCD markersFDA approved drug targetsPredicted intracellular proteinsPredicted membrane proteins |
EVMP score: annotation confidence score.
Extremely high >= 0.85High >= 0.70Medium >= 0.55Low >= 0.40
Basic Information
Protein Names
Urokinase plasminogen activator surface receptor (U-PAR) (uPAR) (Monocyte activation antigen Mo3) (CD antigen CD87)
Protein Class
Cancer-related genesCD markersFDA approved drug targetsPredicted intracellular proteinsPredicted membrane proteins
Protein Function
- Cancer-related genes:Candidate cancer biomarkers
- CD markers
- Predicted intracellular proteins
- FDA approved drug targets:Biotech drugs
Ensembl
Entrez Gene Symbol
Gene Synonym
CD87UPARURKR
Gene Description
Plasminogen activator, urokinase receptor
Chromosome
19
Position
43646095-43670547
Frequency
2
EVMP Score
0.50
Fluorescence & Localization
Cell SpecificAstrocytesSingle-Nuclei Brain SpecificastrocyteBlood Cell Specificneutrophil
Function & Pathway
Protein Function
- Cancer-related genes:Candidate cancer biomarkers
- CD markers
- Predicted intracellular proteins
- FDA approved drug targets:Biotech drugs
Cellular Component
- GO:0005576 extracellular region
- GO:0005788 endoplasmic reticulum lumen
- GO:0005789 endoplasmic reticulum membrane
- GO:0005886 plasma membrane
- GO:0005925 focal adhesion
- GO:0009897 external side of plasma membrane
- GO:0009986 cell surface
- GO:0016020 membrane
- GO:0019898 extrinsic component of membrane
- GO:0035579 specific granule membrane
- GO:0042995 cell projection
- GO:0098637 protein complex involved in cell-matrix adhesion
- GO:1905370 serine-type endopeptidase complex
Molecular Function
Biological Process
Reactome
- R-hsa-162791 attachment of gpi anchor to upar
- R-hsa-75205 dissolution of fibrin clot
- R-hsa-109582 hemostasis
- R-hsa-168249 innate immune system
- R-hsa-6798695 neutrophil degranulation
- R-hsa-163125 post translational modification synthesis of gpi anchored proteins
- R-hsa-597592 post translational protein modification
Mediation Categories
Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediationImmune mediationMetabolism mediationReceptor-signaling mediation
Relations & Evidence
Enzyme-Mediated Modification
1 record.
| Substrate Gene Symbol | Enzyme Gene Symbol | Enzyme UniProt ID | Residue Type | Residue Offset | Modification | Database | References |
|---|---|---|---|---|---|---|---|
| PLAUR | MMP12 | P39900 | T | 108 | cleavage | HPRD | HPRD:12195704 |
Ligand-Receptor Signaling
51 records.
| Category | Parent | Database | Transmitter | Receiver | Secreted | Plasma Membrane (Transmembrane) | Plasma Membrane (Peripheral) |
|---|---|---|---|---|---|---|---|
| receptor | receptor | EMBRACE | No | Yes | Yes | Yes | Yes |
Page 6 of 6Previous
Regulatory Interaction Network
3 records.
Protein Complex Composition
3 records.
| Component Name | Component Gene Symbols | Component UniProt ID | Stoichiometry | Database | Database IDs | References |
|---|---|---|---|---|---|---|
| PLAUR-PLAU complex | PLAUPLAUR | P00749Q03405 | 4:4 | CORUMComplexPortalPDB | intact:EBI-11890834CORUM:7112PDB:3u73PDB:2i9bPDB:2fd6 | 1689240201339422228576116456079100921052567169414755292392021616979660 |
| uPA-uPAR-vitronectin complex | PLAUPLAURVTN | P00749P04004Q03405 | 1:1:1 | ComplexPortalPDB | PDB:3bt2PDB:3u73PDB:2i9bintact:EBI-11892130PDB:4k24PDB:3bt1 | 24465541147552921837641510722842 |
| PLAUR | Q03405 | 8 | PDB | PDB:7v63PDB:7e17PDB:1ywh |
Isolation & Detection Technology
1 record.
| EV Isolation Method | Detection Method | Number of References | References |
|---|---|---|---|
| Differential Ultracentrifugation | Mass spectrometry | 1 | 28914500 |
Sequence, Structure & Domains
Sequences
Length
335
Mass
36,978
Sequence
MGHPPLLPLLLLLHTCVPASWGLRCMQCKTNGDCRVEECALGQDLCRTTIVRLWEEGEELELVEKSCTHSEKTNRTLSYRTGLKITSLTEVVCGLDLCNQGNSGRAVTYSRSRYLECISCGSSDMSCERGRHQSLQCRSPEEQCLDVVTHWIQEGEEGRPKDDRHLRGCGYLPGCPGSNGFHNNDTFHFLKCCNTTKCNEGPILELENLPQNGRQCYSCKGNSTHGCSSEETFLIDCRGPMNQCLVATGTHEPKNQSYMVRGCATASMCQHAHLGDAFSMNHIDVSCCTKSGCNHPDLDVQYRSGAAPQPGPAHLSLTITLLMTARLWGGTLLWT
Alternative Products
Event=Alternative splicing; Named isoforms=3; Name=1; Synonyms=uPAR1, GPI-anchored; IsoId=Q03405-1; Sequence=Displayed; Name=2; Synonyms=uPAR2, Secreted; IsoId=Q03405-2; Sequence=VSP_006715; Name=3; IsoId=Q03405-3; Sequence=VSP_046345, VSP_046346
Alternative Sequence
158..202; Missing (in isoform 3); 203; I -> V (in isoform 3); 253..335; PKNQSYMVRGCATASMCQHAHLGDAFSMNHIDVSCCTKSGCNHPDLDVQYRSGAAPQPGPAHLSLTITLLMTARLWGGTLLWT -> RSLWGSWLPCKSTTALRPPCCEEAQATHV (in isoform 2)
3D Structural Models
Turn
96..99; 122..130; 196..199; 223..225; 229..231; 252..255; 291..294
Helix
206..208; 266..268; 275..278; 296..298
Beta Strand
24..28; 34..38; 45..54; 60..68; 75..81; 84..93; 110..114; 116..121; 133..136; 138..141; 143..150; 155..158; 164..171; 176..183; 186..193; 211..222; 226..228; 233..238; 243..251; 256..264; 270..273; 284..288
3D Structure
X-ray crystallography (11)
Domain & Motif Annotations
Domain (FT)
23..114; UPAR/Ly6 1; 115..213; UPAR/Ly6 2; 214..305; UPAR/Ly6 3
Clinical Relevance
Disease Involvement
Cancer-related genesFDA approved drug targets
Related Diseases
Biomarker
Phase 1/2; Approved; Phase 3
Drug Targets
FDA approved drug targets
Drugs
Interaction Protein
ENSG00000122861
Interaction Count
1
Interaction Dataset
intact_biogrid